<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00908570</url>
  </required_header>
  <id_info>
    <org_study_id>5.1</org_study_id>
    <nct_id>NCT00908570</nct_id>
  </id_info>
  <brief_title>Topical Estriol for Vaginal Health</brief_title>
  <official_title>Topical Estriol for Vaginal Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tulane University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Magee-Women's Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase I study is to investigate and document the effects of local&#xD;
      treatment with a topical estriol cream on the vaginal environment of pre-menopausal women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is evidence from human studies that estrogen can give rise to health-promoting changes&#xD;
      in the vaginal environment in addition to affecting the thickness of the vaginal epithelium.&#xD;
      The purpose of the proposed study is to take the first steps in testing the effects of local&#xD;
      estrogen treatment on vaginal health parameters in humans. We have chosen an estriol product&#xD;
      because, in comparison with estrone (E1) and estradiol (E2), estriol (E3) is generally&#xD;
      considered to be a weak estrogen. The duration of estriol's interaction with the estrogen&#xD;
      receptor is quick and exhibits rapid metabolic clearance. We have chosen a topical route of&#xD;
      administration because it appears to result in fewer systemic effects than oral&#xD;
      administration, while allowing us to concentrate treatment locally in the areas we wish to&#xD;
      affect.&#xD;
&#xD;
      Our primary goal is to test whether or not topically applied estrogen results in significant&#xD;
      thickening and maturation of the vaginal epithelium. Our secondary goal is to measure the&#xD;
      treatment's effects on other parameters of the vagina, such as Lactobacillus colonization and&#xD;
      vaginal pH. If estrogen cream does indeed affect the vaginal environment in pre-menopausal&#xD;
      women as it does in post-menopausal women, further study would be indicated to determine&#xD;
      whether estrogen cream in the vagina decreases risk of infection in pre-menopausal women.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in thickness of the vaginal epithelium</measure>
    <time_frame>Pre and post treatment luteal and follicular phases</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other vaginal parameters including Lactobacillus colonization and vaginal pH</measure>
    <time_frame>Pre and post treatment follicular and luteal phases</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Vaginal Health</condition>
  <arm_group>
    <arm_group_label>1Topical estriol cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2Placebo cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estriol</intervention_name>
    <description>4 ml vaginal cream (1.0 mg estriol/1 ml cream), 3 days/week for approximately 2 months.</description>
    <arm_group_label>1Topical estriol cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo cream</description>
    <arm_group_label>2Placebo cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  In generally good health&#xD;
&#xD;
          -  Between the ages of 18 and 40&#xD;
&#xD;
          -  Report regular, consistent menstrual cycles with duration between 25 and 35 days'&#xD;
             duration&#xD;
&#xD;
          -  Agree not to initiate hormonal contraception or other systemic or vaginal hormonal&#xD;
             treatments during the course of the study&#xD;
&#xD;
          -  Agree to refrain from vaginal douching and use of spermicides, spermicide-treated&#xD;
             condoms, diaphragms, cervical caps, vaginal hygiene treatments and other vaginal&#xD;
             products during the course of the study except as explicitly allowed under study&#xD;
             protocol.&#xD;
&#xD;
          -  Not attempting to get pregnant (and, if sexually active, using an allowed effective&#xD;
             contraceptive - i.e., sterilization or male condoms)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has been informed by a health practitioner that she should avoid estrogen treatments&#xD;
&#xD;
          -  Does not meet one or more of the above inclusion criteria&#xD;
&#xD;
          -  Is currently pregnant&#xD;
&#xD;
          -  Is currently lactating&#xD;
&#xD;
          -  Has IUD in place&#xD;
&#xD;
          -  Has diabetes that is controlled with medication&#xD;
&#xD;
          -  Has menstrual bleeding that usually exceeds 7 days' duration&#xD;
&#xD;
          -  Has used hormonal contraception or other systemic or vaginal hormonal treatment during&#xD;
             the past three months&#xD;
&#xD;
          -  Has received systemic antibiotic treatment since the start of bleeding in her current&#xD;
             menstrual period&#xD;
&#xD;
          -  Has known history of diagnosis of HIV infection&#xD;
&#xD;
          -  Screens positive for gonorrhea, Chlamydia, or trichomonas&#xD;
&#xD;
          -  Has evidence of high-grade dysplasia or cervical cancer on visual examination or Pap&#xD;
             smear&#xD;
&#xD;
          -  Has active genital Herpes lesions&#xD;
&#xD;
          -  Has any of the following:&#xD;
&#xD;
          -  Known, past or suspected breast cancer;&#xD;
&#xD;
          -  Known or suspected estrogen-dependent malignant or pre-malignant tumours (e.g&#xD;
             endometrial cancer);&#xD;
&#xD;
          -  History of endometrial hyperplasia;&#xD;
&#xD;
          -  Undiagnosed or abnormal genital bleeding;&#xD;
&#xD;
          -  Previous idiopathic or current venous thromboembolism (deep venous thrombosis,&#xD;
             pulmonary embolism);&#xD;
&#xD;
          -  Active or recent arterial thromboembolic disease (e.g. angina, myocardial infarction);&#xD;
&#xD;
          -  Acute liver disease, or a history of liver disease where liver function tests have&#xD;
             failed to return to normal;&#xD;
&#xD;
          -  Liver disorders such as adenomas;&#xD;
&#xD;
          -  Symptomatic gallstones or gallbladder disease (cholecystitis);&#xD;
&#xD;
          -  Hypertriglyceridemia;&#xD;
&#xD;
          -  Vascular disease associated with lupus erythematosus;&#xD;
&#xD;
          -  Known hypersensitivity to estriol (estrogen E3) or the inactive substances in the&#xD;
             study product;&#xD;
&#xD;
          -  Porphyria&#xD;
&#xD;
          -  Presents any other history or condition that provider, in his or her best discretion,&#xD;
             feels should rule out study participation.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yael Swica, M.D., M.P.H.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>May 26, 2009</study_first_submitted>
  <study_first_submitted_qc>May 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2009</study_first_posted>
  <last_update_submitted>March 3, 2011</last_update_submitted>
  <last_update_submitted_qc>March 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Beverly Winikoff, MD, MPH</name_title>
    <organization>Gynuity Health Projects</organization>
  </responsible_party>
  <keyword>estrogen</keyword>
  <keyword>estriol</keyword>
  <keyword>cream</keyword>
  <keyword>vagina</keyword>
  <keyword>infection prevention</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

